Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for moderate COVID-19 pneumonia
IRCT20200428047232N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Time to clinical recovery. Started May 2020; status: completed.
02
Drugs
thalidomide
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200428047232N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200428047232N1.